Nicox Sa EUR Ord (NICXF) 2.0000 $NICXF
Retinal Vein Occlusion - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ws2jkc/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerpio Therapeutics, Inc. - Allergan, Inc. - Avalanche Biotechnologies, Inc. - F. Hoffmann-La Roche Ltd. - Kala Pharmaceuticals, Inc. - Mabion SA - NicOx S.A. - Ohr Pharmaceutical Inc. - pSivida Corp. - Regeneron Pharmaceuticals, Inc. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/ws...tinal_vein
AGN: 312.13 (+8.03), OHRP: 2.27 (-0.07), AAVL: 16.25 (+0.62), REGN: 526.01 (+16.98)
Global Duchenne Muscular Dystrophy Therapeutics Pipeline Review, H1 2015
M2 - Mon Jun 08, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ppgk5r/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Asklepios BioPharmaceutical, Inc. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Eli Lilly and Company - EryDel SPA - Fate Therapeutics, Inc. - Galapagos NV - Genethon - Idera Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Marathon Pharmaceuticals, LLC - Marina Biotech, Inc. - miRagen Therapeutics, Inc. - NicOx S.A. - Nippon Shinyaku Co., Ltd. - nLife Therapeutics, S.L. - Nobelpharma Co., Ltd. - Pfizer Inc. - Prosensa Therapeutics B.V. - Prothelia, Inc. - PTC Therapeutics, Inc. - Reata Pharmaceuticals, Inc. - Retrophin Inc. - ReveraGen BioPharma, Inc. - Sanofi - Santhera Pharmaceuticals Holding AG - Sarepta Therapeutics, Inc. - Shenzhen Beike Biotechnology Co., Ltd. - Shire Plc - Summit Corporation plc - Taiho Pharmaceutical Co., Ltd. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/pp...e_muscular
FATE: 7.25 (unch), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), GLPG: 53.06 (+0.56), IDRA: 3.49 (+0.05), SHPG: 250.34 (+7.35), SRPT: 30.02 (+0.66), RTRX: 33.59 (+1.88), PTCT: 46.49 (+1.75), SMMT: 11.27 (+0.06), XLRN: 30.03 (+0.20)
Allergic Conjunctivitis - Pipeline Review, H1 2015 Includes Late-stage and Discontinued Projects
M2 - Mon Jun 08, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js2p9k/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H1 2015" report to their offering. . This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Alcon, Inc. - Allergan, Inc. - Celsus Therapeutics Plc - Eleven Biotherapeutics Inc. - Griffin Discoveries BV - Laila Pharmaceuticals Pvt. Ltd. - NicOx S.A. - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Oxagen Limited - Sun Pharma Advanced Research Company Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/js2p9k/allergic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 312.13 (+8.03), OHRP: 2.27 (-0.07), CLTX: 0.49 (-0.02), XNCR: 22.60 (+0.13), OCUL: 20.82 (+0.73)
Global Ocular Pain Therapeutics Pipeline Review, H1 2015 - 8 Companies & 11 Drug Profiles
M2 - Fri Jun 05, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72mmmt/ocular_pain) has announced the addition of the "Ocular Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Auven Therapeutics Management L.L.L.P - Bayer AG - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - NicOx S.A. - Reata Pharmaceuticals, Inc. - Sylentis S.A. - Valeant Pharmaceuticals International, Inc. Drug Profiles - fluticasone propionate - ISV-303 - ketorolac tromethamine - loteprednol etabonate - loteprednol etabonate next generation - mapracorat - NT-71 - NT-72 - RTA-408 - RX-10045 - SYL-1001 For more information visit http://www.researchandmarkets.com/research/72...cular_pain
VRX.TO: 294.65 (+11.22), PTIE: 1.70 (unch)
InSite Vision Reports First Quarter 2015 Financial Results
Business Wire - Tue May 12, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter ended March 31, 2015. Revenues for the quarter ended March 31, 2015 were $3.4 million compared to $1.2 million for the same period in 2014; increase in revenues was due to a $3.0 million upfront license payment. Net loss for the quarter ended March 31, 2015 was $0.8 million, or $0.01 per share, compared to a net loss of $4.7 million, or $0.04 per share, in 2014. As of March 31, 2015, cash and cash equivalents totaled $1.1 million.
Promising preclinical data on new compounds for glaucoma presented at ARVO by Nicox
GlobeNewswire - Mon May 11, 12:34AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced that promising preclinical results from two novel nitric oxide-donors, NCX 667 and NCX 470, were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting, held from May 3 to May 7, 2015, in Denver, Colorado.
Nicox: Implementation of a liquidity contract with Gilbert Dupont
GlobeNewswire - Mon Apr 27, 12:56AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced the implementation of a liquidity contract.
Nicox's Extraordinary and Ordinary Shareholder Meetings
GlobeNewswire - Fri Apr 24, 3:08AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), has convened an ordinary and extraordinary shareholder meeting on Wednesday June 3, 2015 at 2:00 pm CET at the Hotel Mercure - rue Albert Caquot - 06560 Sophia Antipolis - France.
Nicox first quarter 2015 financial and business update
GlobeNewswire - Fri Apr 17, 12:43AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today reported its first quarter 2015 revenues and cash position and provided an update on its activities.
Nicox receives Orphan Drug Designation from FDA for naproxcinod in Duchenne Muscular Dystrophy
GlobeNewswire - Thu Mar 19, 1:37AM CDT
Nicox S.A. (Euronext Paris: COX) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for naproxcinod for the treatment of Duchenne Muscular Dystrophy (DMD). ODD is a status granted to drugs or biological products that treat rare diseases or conditions. The designation qualifies the sponsor of the drug for various development incentives, including a period of US marketing exclusivity upon marketing approval for the designated indication, potential tax credits and the waiver of certain fees.
InSite Vision Announces License Agreement for AzaSite(R), AzaSite Xtra(TM) and BromSite(TM) in Europe, Middle East and Africa
Business Wire - Mon Feb 02, 7:30AM CST
InSite Vision Incorporated (OTCBB:INSV) today announced that it has entered into a license agreement with Nicox S.A. (NYSE Euronext Paris: COX), a France-based publicly traded company, for the development and commercialization of InSite's innovative ophthalmic therapeutic products AzaSite (1% azithromycin), AzaSite Xtra (2% azithromycin) and BromSite (0.075% bromfenac) all formulated in InSite's DuraSite(R) drug delivery system. The agreement grants Nicox exclusive rights to commercialize all three products in Europe (including Eastern Europe), Middle East and Africa (EMEA). Nicox expects to file European Marketing Authorizations (MAAs) for AzaSite and BromSite by first quarter 2016 with first commercial launch in late 2017.
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 388.23 (-11.06), PSTI: 2.40 (+0.03), ASPX: 100.96 (unch), LPTN: 0.28 (unch), IBIO: 0.86 (+0.01), FGEN: 22.82 (+0.58), AQXP: 1.94 (-0.19), GALT: 2.67 (+0.12), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), GILD: 113.74 (+0.38), CGEN: 6.63 (+0.06), FPRX: 26.01 (+0.37), CELGZ: 2.15 (+0.14)
Nicox holds successful pre-NDA meeting with FDA on AC-170 clinical package
GlobeNewswire - Mon Jan 26, 12:35AM CST
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has held a positive pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) regarding AC-170, a topical ocular formulation of cetirizine developed for the treatment of ocular itching associated with allergic conjunctivitis. The purpose of the meeting was to discuss the clinical package for AC-170, and based on the available efficacy and safety data, the Agency recommended submission of the NDA. Nicox will hold an additional pre-NDA meeting regarding the Chemistry, Manufacturing and Controls (CMC) data package, which is expected to take place in the first quarter of 2015. Nicox will update the market in due course on the expected NDA submission date.
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 5.22 (+0.14), ITEK: 5.11 (+0.25), NBS: 2.25 (-0.09), FOMX: 11.18 (+0.22), AERI: 17.80 (+0.12), OCUL: 20.82 (+0.73), AGN: 312.13 (+8.03), CANF: 2.00 (+0.09), ACAD: 43.94 (+1.76), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75), OHRP: 2.27 (-0.07), CBMG: 29.80 (+0.31)
Seborrhea Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Fri Jan 02, 4:30PM CST
The report "Seborrhea Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Seborrhea. Seborrhea is a common skin problem. It causes a red, itchy rash and white scales. It particularly affects the sebaceous-gland-rich areas of skin such as scalp, face and torso. Seborrhoeic dermatitis symptoms appear gradually and usually the first signs are flaky skin and scalp. Adults of all ages may develop seborrhea, too, especially on the scalp and face. Complete Report is Available @ http://www.reportsnreports.com/reports/321896...-2014.html .
VRX.TO: 294.65 (+11.22)
Duchenne Muscular Dystrophy - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/rxfljh/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Eli Lilly and Company - Daiichi Sankyo Company - Nippon Shinyaku - Zambon - Sarepta - NicOx - Lexicon - Galapagos - Summit - Santhera - Shenzhen Beike Biotechnology - Italfarmaco - Acceleron - Prosensa - Catabasis - Nobelpharma - PTC - Reata - Fate - N-Gene - Asklepios - Genethon - miRagen - Prosensa - Tarix - EryDel - Myomics - Prothelia - ReveraGen BioPharma - Retrophin For more information visit http://www.researchandmarkets.com/research/rx...e_muscular
LLY: 88.29 (+0.81)
Nicox completes the acquisition of Aciex Therapeutics, Inc.
GlobeNewswire - Mon Oct 27, 1:35AM CDT
Nicox S.A. (NYSE Euronext Paris: COX) today announced the completion of the acquisition of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company. This acquisition represents a significant step forward in Nicox's strategy of creating an international ophthalmic company and will significantly broaden and strengthen Nicox's therapeutic development pipeline.
Nicox's shareholders approve acquisition of Aciex Therapeutics, Inc.
GlobeNewswire - Wed Oct 22, 10:37AM CDT
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that its shareholders voted to approve the acquisition of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company, at the General Meeting held today October 22, 2014, with more than 97% of votes in favour. The transaction is expected to be completed within the next few days, following the completion of certain legal conditions and formalities. All the other resolutions submitted to the General Meeting were also approved.
Nicox's Jerry St. Peter nominated to TFOS Corporate Advisory Board
GlobeNewswire - Thu Oct 16, 12:33AM CDT
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that Jerry St. Peter, Executive Vice President and General Manager of Nicox's US subsidiary Nicox Inc., has been nominated to the Corporate Advisory Board of the Tear Film & Ocular Surface Society (TFOS). TFOS is an international, non-profit eye health organization dedicated to advancing research and education related to the scientific field of the surface of the eye.
Nicox launches Xailin Gel, an innovative "preservative-free in the eye" dry eye lubricant
GlobeNewswire - Tue Oct 14, 12:38AM CDT
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced the launch in Europe of Xailin Gel, an innovative multidose carbomer gel lubricant (medical device) that becomes preservative-free in the eye. Once Xailin Gel is in contact with the eye surface, the substance released by the preservative is converted to water and oxygen by ocular enzymes, making Xailin Gel 'preservative-free in the eye'. Xailin Gel follows Xailin Night and Xailin Fresh as the third medical device to be introduced in the Xailin(TM) range of dry eye lubricants.
Retinal Vein Occlusion - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ws2jkc/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerpio Therapeutics, Inc. - Allergan, Inc. - Avalanche Biotechnologies, Inc. - F. Hoffmann-La Roche Ltd. - Kala Pharmaceuticals, Inc. - Mabion SA - NicOx S.A. - Ohr Pharmaceutical Inc. - pSivida Corp. - Regeneron Pharmaceuticals, Inc. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/ws...tinal_vein
AGN: 312.13 (+8.03), OHRP: 2.27 (-0.07), AAVL: 16.25 (+0.62), REGN: 526.01 (+16.98)
Global Duchenne Muscular Dystrophy Therapeutics Pipeline Review, H1 2015
M2 - Mon Jun 08, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ppgk5r/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Asklepios BioPharmaceutical, Inc. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Eli Lilly and Company - EryDel SPA - Fate Therapeutics, Inc. - Galapagos NV - Genethon - Idera Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Marathon Pharmaceuticals, LLC - Marina Biotech, Inc. - miRagen Therapeutics, Inc. - NicOx S.A. - Nippon Shinyaku Co., Ltd. - nLife Therapeutics, S.L. - Nobelpharma Co., Ltd. - Pfizer Inc. - Prosensa Therapeutics B.V. - Prothelia, Inc. - PTC Therapeutics, Inc. - Reata Pharmaceuticals, Inc. - Retrophin Inc. - ReveraGen BioPharma, Inc. - Sanofi - Santhera Pharmaceuticals Holding AG - Sarepta Therapeutics, Inc. - Shenzhen Beike Biotechnology Co., Ltd. - Shire Plc - Summit Corporation plc - Taiho Pharmaceutical Co., Ltd. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/pp...e_muscular
FATE: 7.25 (unch), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), GLPG: 53.06 (+0.56), IDRA: 3.49 (+0.05), SHPG: 250.34 (+7.35), SRPT: 30.02 (+0.66), RTRX: 33.59 (+1.88), PTCT: 46.49 (+1.75), SMMT: 11.27 (+0.06), XLRN: 30.03 (+0.20)
Allergic Conjunctivitis - Pipeline Review, H1 2015 Includes Late-stage and Discontinued Projects
M2 - Mon Jun 08, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js2p9k/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H1 2015" report to their offering. . This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Alcon, Inc. - Allergan, Inc. - Celsus Therapeutics Plc - Eleven Biotherapeutics Inc. - Griffin Discoveries BV - Laila Pharmaceuticals Pvt. Ltd. - NicOx S.A. - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Oxagen Limited - Sun Pharma Advanced Research Company Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/js2p9k/allergic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 312.13 (+8.03), OHRP: 2.27 (-0.07), CLTX: 0.49 (-0.02), XNCR: 22.60 (+0.13), OCUL: 20.82 (+0.73)
Global Ocular Pain Therapeutics Pipeline Review, H1 2015 - 8 Companies & 11 Drug Profiles
M2 - Fri Jun 05, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72mmmt/ocular_pain) has announced the addition of the "Ocular Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Auven Therapeutics Management L.L.L.P - Bayer AG - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - NicOx S.A. - Reata Pharmaceuticals, Inc. - Sylentis S.A. - Valeant Pharmaceuticals International, Inc. Drug Profiles - fluticasone propionate - ISV-303 - ketorolac tromethamine - loteprednol etabonate - loteprednol etabonate next generation - mapracorat - NT-71 - NT-72 - RTA-408 - RX-10045 - SYL-1001 For more information visit http://www.researchandmarkets.com/research/72...cular_pain
VRX.TO: 294.65 (+11.22), PTIE: 1.70 (unch)
InSite Vision Reports First Quarter 2015 Financial Results
Business Wire - Tue May 12, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter ended March 31, 2015. Revenues for the quarter ended March 31, 2015 were $3.4 million compared to $1.2 million for the same period in 2014; increase in revenues was due to a $3.0 million upfront license payment. Net loss for the quarter ended March 31, 2015 was $0.8 million, or $0.01 per share, compared to a net loss of $4.7 million, or $0.04 per share, in 2014. As of March 31, 2015, cash and cash equivalents totaled $1.1 million.
Promising preclinical data on new compounds for glaucoma presented at ARVO by Nicox
GlobeNewswire - Mon May 11, 12:34AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced that promising preclinical results from two novel nitric oxide-donors, NCX 667 and NCX 470, were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting, held from May 3 to May 7, 2015, in Denver, Colorado.
Nicox: Implementation of a liquidity contract with Gilbert Dupont
GlobeNewswire - Mon Apr 27, 12:56AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced the implementation of a liquidity contract.
Nicox's Extraordinary and Ordinary Shareholder Meetings
GlobeNewswire - Fri Apr 24, 3:08AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), has convened an ordinary and extraordinary shareholder meeting on Wednesday June 3, 2015 at 2:00 pm CET at the Hotel Mercure - rue Albert Caquot - 06560 Sophia Antipolis - France.
Nicox first quarter 2015 financial and business update
GlobeNewswire - Fri Apr 17, 12:43AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today reported its first quarter 2015 revenues and cash position and provided an update on its activities.
Nicox receives Orphan Drug Designation from FDA for naproxcinod in Duchenne Muscular Dystrophy
GlobeNewswire - Thu Mar 19, 1:37AM CDT
Nicox S.A. (Euronext Paris: COX) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for naproxcinod for the treatment of Duchenne Muscular Dystrophy (DMD). ODD is a status granted to drugs or biological products that treat rare diseases or conditions. The designation qualifies the sponsor of the drug for various development incentives, including a period of US marketing exclusivity upon marketing approval for the designated indication, potential tax credits and the waiver of certain fees.
InSite Vision Announces License Agreement for AzaSite(R), AzaSite Xtra(TM) and BromSite(TM) in Europe, Middle East and Africa
Business Wire - Mon Feb 02, 7:30AM CST
InSite Vision Incorporated (OTCBB:INSV) today announced that it has entered into a license agreement with Nicox S.A. (NYSE Euronext Paris: COX), a France-based publicly traded company, for the development and commercialization of InSite's innovative ophthalmic therapeutic products AzaSite (1% azithromycin), AzaSite Xtra (2% azithromycin) and BromSite (0.075% bromfenac) all formulated in InSite's DuraSite(R) drug delivery system. The agreement grants Nicox exclusive rights to commercialize all three products in Europe (including Eastern Europe), Middle East and Africa (EMEA). Nicox expects to file European Marketing Authorizations (MAAs) for AzaSite and BromSite by first quarter 2016 with first commercial launch in late 2017.
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 388.23 (-11.06), PSTI: 2.40 (+0.03), ASPX: 100.96 (unch), LPTN: 0.28 (unch), IBIO: 0.86 (+0.01), FGEN: 22.82 (+0.58), AQXP: 1.94 (-0.19), GALT: 2.67 (+0.12), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), GILD: 113.74 (+0.38), CGEN: 6.63 (+0.06), FPRX: 26.01 (+0.37), CELGZ: 2.15 (+0.14)
Nicox holds successful pre-NDA meeting with FDA on AC-170 clinical package
GlobeNewswire - Mon Jan 26, 12:35AM CST
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has held a positive pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) regarding AC-170, a topical ocular formulation of cetirizine developed for the treatment of ocular itching associated with allergic conjunctivitis. The purpose of the meeting was to discuss the clinical package for AC-170, and based on the available efficacy and safety data, the Agency recommended submission of the NDA. Nicox will hold an additional pre-NDA meeting regarding the Chemistry, Manufacturing and Controls (CMC) data package, which is expected to take place in the first quarter of 2015. Nicox will update the market in due course on the expected NDA submission date.
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 5.22 (+0.14), ITEK: 5.11 (+0.25), NBS: 2.25 (-0.09), FOMX: 11.18 (+0.22), AERI: 17.80 (+0.12), OCUL: 20.82 (+0.73), AGN: 312.13 (+8.03), CANF: 2.00 (+0.09), ACAD: 43.94 (+1.76), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75), OHRP: 2.27 (-0.07), CBMG: 29.80 (+0.31)
Seborrhea Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Fri Jan 02, 4:30PM CST
The report "Seborrhea Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Seborrhea. Seborrhea is a common skin problem. It causes a red, itchy rash and white scales. It particularly affects the sebaceous-gland-rich areas of skin such as scalp, face and torso. Seborrhoeic dermatitis symptoms appear gradually and usually the first signs are flaky skin and scalp. Adults of all ages may develop seborrhea, too, especially on the scalp and face. Complete Report is Available @ http://www.reportsnreports.com/reports/321896...-2014.html .
VRX.TO: 294.65 (+11.22)
Duchenne Muscular Dystrophy - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/rxfljh/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Eli Lilly and Company - Daiichi Sankyo Company - Nippon Shinyaku - Zambon - Sarepta - NicOx - Lexicon - Galapagos - Summit - Santhera - Shenzhen Beike Biotechnology - Italfarmaco - Acceleron - Prosensa - Catabasis - Nobelpharma - PTC - Reata - Fate - N-Gene - Asklepios - Genethon - miRagen - Prosensa - Tarix - EryDel - Myomics - Prothelia - ReveraGen BioPharma - Retrophin For more information visit http://www.researchandmarkets.com/research/rx...e_muscular
LLY: 88.29 (+0.81)
Nicox completes the acquisition of Aciex Therapeutics, Inc.
GlobeNewswire - Mon Oct 27, 1:35AM CDT
Nicox S.A. (NYSE Euronext Paris: COX) today announced the completion of the acquisition of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company. This acquisition represents a significant step forward in Nicox's strategy of creating an international ophthalmic company and will significantly broaden and strengthen Nicox's therapeutic development pipeline.
Nicox's shareholders approve acquisition of Aciex Therapeutics, Inc.
GlobeNewswire - Wed Oct 22, 10:37AM CDT
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that its shareholders voted to approve the acquisition of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company, at the General Meeting held today October 22, 2014, with more than 97% of votes in favour. The transaction is expected to be completed within the next few days, following the completion of certain legal conditions and formalities. All the other resolutions submitted to the General Meeting were also approved.
Nicox's Jerry St. Peter nominated to TFOS Corporate Advisory Board
GlobeNewswire - Thu Oct 16, 12:33AM CDT
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that Jerry St. Peter, Executive Vice President and General Manager of Nicox's US subsidiary Nicox Inc., has been nominated to the Corporate Advisory Board of the Tear Film & Ocular Surface Society (TFOS). TFOS is an international, non-profit eye health organization dedicated to advancing research and education related to the scientific field of the surface of the eye.
Nicox launches Xailin Gel, an innovative "preservative-free in the eye" dry eye lubricant
GlobeNewswire - Tue Oct 14, 12:38AM CDT
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced the launch in Europe of Xailin Gel, an innovative multidose carbomer gel lubricant (medical device) that becomes preservative-free in the eye. Once Xailin Gel is in contact with the eye surface, the substance released by the preservative is converted to water and oxygen by ocular enzymes, making Xailin Gel 'preservative-free in the eye'. Xailin Gel follows Xailin Night and Xailin Fresh as the third medical device to be introduced in the Xailin(TM) range of dry eye lubricants.
